Goldman Sachs Lowers PT on Tenet Healthcare to $5
Goldman Sachs has published a research report on Tenet Healthcare (NYSE: THC) and has lowered the price target on the company from $5.50 to $5.
In the report, Goldman Sachs writes, "We have updated our model including revisions to our forecasted revenue, EBTIDA and EPS. These changes reflect an updated view of THC's operating metrics and also our view that utilization demand will remain weak in 2012-2013 while pressure on reimbursement will increase somewhat. Accordingly, we have lowered our 4Q11 EPS to 0.14 from 0.18 and our 2012-13 EPS numbers to $0.48 and $0.55 from $0.63 and $0.70. We have also adjusted our 2010-11 non-GAAP EPS numbers, which now exclude impairment and litigation charges."
Goldman Sachs maintains its Neutral rating on Tenet Healthcare, which is currently trading up $0.31 from yesterday's $4.42 closing price.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.